Filtered By:
Condition: Atrial Fibrillation
Drug: Amiodarone

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 93 results found since Jan 2013.

Pulmonary Hypertension due to Radiofrequency Catheter Ablation (RFCA) for Atrial Fibrillation: The Lungs, the Atrium or the Ventricle?
Atrial fibrillation is the most common heart rhythm disorder affecting around 2.5 million people in United States. It is characterised by rapid and irregular beating of both the atria resulting in the similar ventricular response. It is associated with the risk of stroke and heart failure resulting in increased morbidity and mortality [1]. The treatment of atrial fibrillation involves rate control with ant-arrhythmic drugs like beta blockers, digoxin and amiodarone. Cardioversion is recommended in case of haemodynamic instability or after failure of pharmacological therapies.
Source: Heart, Lung and Circulation - July 15, 2016 Category: Cardiology Authors: Isha Verma, Hemantkumar Tripathi, Rutuja Rajanikant Sikachi, Abhinav Agrawal Tags: Review Source Type: research

Evaluation of early direct current cardioversion for maintenance of sinus rhythm in rheumatic atrial fibrillation following successful balloon mitral valvotomy.
CONCLUSION: In patients with rheumatic MS and AF, early DCCV and a short-duration oral Amiodarone, following successful PBMV, may be a reasonable strategy to attain long-term SR. PMID: 27543470 [PubMed - in process]
Source: Indian Heart J - June 30, 2016 Category: Cardiology Authors: Sharma G, Anantha Krishnan R, Bohra V, Ramakrishnan S, Naik N, Seth S, Juneja R, Kalaivani M, Bahl VK Tags: Indian Heart J Source Type: research

Polish and European management strategies in patients with atrial fibrillation. Data from the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot).
CONCLUSIONS    A rhythm control-oriented strategy in patients with AF with the use of ablation in cardiology wards is more frequent in Poland than in other EU countries. Similar to other EU countries, compliance with the ESC guidelines regarding anticoagulation in AF patients is suboptimal in Poland. Undertreatment was observed in a significant proportion of patients at high risk of stroke, while a large group of low-risk patients are overtreated. Differences between the types of recruiting centers in Poland and other EU countries might have influenced the results. PMID: 27000745 [PubMed - as supplied by publisher]
Source: Polskie Archiwum Medycyny Wewnetrznej - March 25, 2016 Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research

Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants Cardiovascular Perspective
Anticoagulation clinics were initially developed to provide safe and effective care for warfarin-treated patients with atrial fibrillation, venous thromboembolism, and mechanical valve replacement. Traditionally, these patients required ongoing laboratory monitoring and warfarin dose adjustment by expert providers. With the introduction of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban), many have questioned the need for anticoagulation clinic. However, we think that the growing number of oral anticoagulant choices creates an urgent need for expanding the traditional role of the anticoagulation...
Source: Circulation: Cardiovascular Quality and Outcomes - March 15, 2016 Category: Cardiology Authors: Barnes, G. D., Nallamothu, B. K., Sales, A. E., Froehlich, J. B. Tags: Atrial Fibrillation, Ethics and Policy, Health Services, Ischemic Stroke, Thrombosis Cardiovascular Perspective Source Type: research

Evaluation of early direct current cardioversion for maintenance of sinus rhythm in rheumatic atrial fibrillation following successful balloon mitral valvotomy
Conclusion In patients with rheumatic MS and AF, early DCCV and a short-duration oral Amiodarone, following successful PBMV, may be a reasonable strategy to attain long-term SR.
Source: Indian Heart Journal - March 3, 2016 Category: Cardiology Source Type: research

Topical amiodarone to prevent postoperative atrial fibrillation: Need for further study
Postoperative atrial fibrillation (AF) is a common complication after cardiac surgery that increases hospital stay and the risk of stroke.1 Prophylactic systemic administration of amiodarone in the perioperative period prevents postoperative AF2; however, its challenging side-effect profile limits its routine and widespread use as prophylaxis.3 It was therefore with great interest that we recently read the report by Feng and colleagues4 describing their success in applying a topical amiodarone-releasing hydrogel on the atrial surface during coronary artery bypass grafting operations.
Source: The Journal of Thoracic and Cardiovascular Surgery - January 23, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Jordan Beau, Alexander Kulik Tags: Letter to the editor Source Type: research

Iodine-induced hyperthyroidism as combination of different etiologies: an overlooked entity in the elderly.
We report the case of an elderly man who was diagnosed with tachyfibrillation secondary to hyperthyroidism. Thyroid hyperfunction was subsequently related both to previous amiodarone therapy (probably mixed form) and the recent use of iodinated contrast medium for computed tomography scan. Thyroid ultrasonography showed a plongeant multinodular goitre. After initial worsening, thyroid function improved slowly but progressively on high-dose thyreostatic therapy combined with steroid therapy; tachyfibrillation caused heart failure and a thrombus in the left atrium, and proved initially resistant to combined antiarrhythmic tr...
Source: Aging Clinical and Experimental Research - November 4, 2015 Category: Geriatrics Authors: Foppiani L, Cascio C, Pinto GL Tags: Aging Clin Exp Res Source Type: research

Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
CONCLUSION: Cardioversion appears as a safe procedure with a reasonably acceptable cardiovascular event rate. However, to prevent the cardiovascular events, several risk factors should be considered before cardioversion. PMID: 26446636 [PubMed - in process]
Source: Yonsei Medical Journal - October 9, 2015 Category: Universities & Medical Training Authors: Shin DG, Cho I, Hartaigh BÓ, Mun HS, Lee HY, Hwang ES, Park JK, Uhm JS, Pak HN, Lee MH, Joung B Tags: Yonsei Med J Source Type: research

Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin　- Insights From the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: HDE had a greater relative efficacy and safety in EA compared with Japan that was only partially explained by differences in baseline characteristics and TTR. PMID: 26460886 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 9, 2015 Category: Cardiology Authors: Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, Mercuri M, Ruff CT, Giugliano RP Tags: Circ J Source Type: research

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbuchel, H., Camm, A. J., Antman, E. M., Ruff, C. T. Tags: Thrombosis and anti-thrombotic therapy Source Type: research

Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
CONCLUSION: Compared with dronedarone, amiodarone, class 1C agents, and sotalol are more effective for rhythm control, while dofetilide had similar efficacy. These findings have important implications for clinical practice. PMID: 26233885 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - July 29, 2015 Category: Cardiology Authors: Qin D, Leef G, Alam MB, Rattan R, Munir MB, Patel D, Khattak F, Adelstein E, Jain SK, Saba S Tags: J Cardiol Source Type: research

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
CONCLUSIONS: Several class IA, IC and III drugs, as well as class II drugs (beta-blockers), are moderately effective in maintaining sinus rhythm after conversion of atrial fibrillation. However, they increase adverse events, including pro-arrhythmia, and some of them (disopyramide, quinidine and sotalol) may increase mortality. Possible benefits on clinically relevant outcomes (stroke, embolism, heart failure) remain to be established. PMID: 25820938 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - April 2, 2015 Category: Journals (General) Authors: Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J Tags: Cochrane Database Syst Rev Source Type: research

A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF STUDY)
Publication date: Available online 21 February 2015 Source:American Heart Journal Author(s): Gregory Y.H. Lip , Jose Merino , Michael Ezekowitz , Kenneth Ellenbogen , Dmitry Zamoryakhin , Hans Lanz , James Jin , Naab Al-Saadi , Michele Mercuri , Andreas Goette We designed a prospective, randomized, open-label, blinded endpoint evaluation(PROBE) parallel group Phase 3b clinical trial comparing edoxaban (a new oral factor Xa inhibitor) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of non-valvular AF. The primary efficacy endpoint is the composite endpoints of st...
Source: American Heart Journal - February 25, 2015 Category: Cardiology Source Type: research

Thromboembolic Events 7–11 Years after Catheter Ablation of Atrial Fibrillation
ConclusionsOur study shows low TE rates 9 years after ablation of AF that are lower than published data for AF patients with anticoagulation only. AF patients with a CHA2DS2‐VASc ≥2 should, however, be maintained on anticoagulation.
Source: Pacing and Clinical Electrophysiology : PACE - January 28, 2015 Category: Cardiology Authors: VAN NAM TRAN, ELENA TESSITORE, PASCALE GENTIL‐BARON, ANNE‐SOPHIE JANNOT, HENRI SUNTHORN, HARAN BURRI, FRANÇOIS MACH, DIPEN SHAH Tags: ORIGINAL ARTICLE Source Type: research

Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation.
Conclusion. Based on current evidence, pulmonary vein ablation for treatment of AF is cost-effective if decision makers willingness to pay for a QALY is $59,194 or higher. PMID: 24089640 [PubMed]
Source: International Journal of Vascular Medicine - December 1, 2014 Category: Cardiology Tags: Int J Vasc Med Source Type: research